NurExone closes CAD2m private placement

Categories: Capital Markets

Biopharmaceutical company, NurExone Biologic Inc. has completed a private placement of CAD2 million.

The Toronto-listed company develops a platform for biologically-guided ExoTherapy using exosomes as a next generation drug delivery system. This placement is further testament to the resilience of the Israeli life sciences sector.

Gowling WLG advised NurExone Biologic on closing this transaction.

Gowling WLG

More details

Subscribe to IsraelDesks Updates

Please sign up to our newsletters to receive information about market trends and relevant events and updates.

I am an Israeli lawyer and wish to receive news from the Israel Desks across the globe I am an international lawyer and want to stay updated on current Israeli market trends and updates

I agree that Nishlis Legal Marketing may store and use the information I provided herein for marketing activities, i.e. the sending of legal publications, notifications of other seminar programmes and for the promotion of Nishlis Legal Marketing services by mail, email, sms and mms . I am aware that I can retract/revoke/withdraw my consent at any time.

Contact IsraelDesks

Get Law Firm Listed on Israel Desks

Please let us know if you would like to feature your international law firm on Israel Desks. We would be more than happy to provide additional information.

Help Me Find an Israeli Desk

We would be more than happy to assist you personally in finding the right address across the globe for your referral work. Please leave us you contact details and additional information and we will get back to you.

Accessibility

Provided by: